Altre lingue Virios Therapeutics, Inc.

Azioni

VIRI

US92829J1043

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 01/05/2024			Variaz. 5gg	Var. 1 gen.
0,4399 ^USD	-2,67%		+3,46%	-23,50%

29/02	Virios Therapeutics, Inc. riporta i risultati degli utili per il quarto trimestre e l'intero anno terminato il 31 dicembre 2023	CI
22/01	Virios Therapeutics annuncia i piani di avanzamento dello sviluppo di Imc-2 come trattamento per i sintomi associati alla sindrome di Long-Covid	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID	26/03
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	01/03
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones	29/02
Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	29/02
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones	28/02
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID	22/01
Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid	22/01
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID	02/01
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID	02/01
Virios Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update	13/11
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023	06/11
Thinking about buying stock in Aware, Virios Therapeutics, Bit Brother, Confluent, or Blue Star Foods?	03/11
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023	12/10/23
Virios Therapeutics, Inc. Announces Termination of At-The-Market Sales Agreement	18/09/23
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement	18/09/23
Virios Therapeutics CEO Greg Duncan to Present at the SHARE Series Investor Event on Monday, September 18, 2023	13/09/23
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023	12/09/23
Virios Therapeutics Announces Halt to At-The-Market Offering Sales	14/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Virios Therapeutics, Inc.

Azioni

VIRI

US92829J1043

Altre lingue

Filtri